AbbVie raises full-year profit forecast as Humira fuels sales beat [Reuters]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Reuters
By Reuters Staff 2 Min Read April 30 (Reuters) - AbbVie Inc beat Wall Street estimates for first-quarter revenue on Friday and raised its full-year profit forecast, helped by demand for blockbuster rheumatoid arthritis drug Humira and newer treatments such as psoriasis treatment Skyrizi. Humira sales rose 3.5% to $4.87 billion, beating expectations of $4.78 billion. Sales, however, fell 8.3% in markets outside the United States due to rising competition, especially in Europe. The world’s best selling medicine, approved to treat psoriasis and rheumatoid arthritis, is also expected to face competition in the United States after 2023. AbbVie is now banking on newer treatments such as Skyrizi and rheumatoid arthritis drug Rinvoq to blunt the blow. Sales of Skyrizi surged about 91% to $574 million in the first quarter ended March 31, beating estimates of $569.89 million, according to IBES data from Refinitiv. Net revenues rose nearly 51% to $13.01 billion, ahead of estimates of $12.76 bil
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Why AbbVie Stock Stumbled Today Despite the Earnings Beat [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View [Yahoo! Finance]Yahoo! Finance
- AbbVie's Q1: Positive Surprise [Seeking Alpha]Seeking Alpha
- AbbVie (ABBV) Reports Q1 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
- AbbVie Q1 report beats Street despite plunging Humira sales [Seeking Alpha]Seeking Alpha
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 4/26/24 - Form 8-K
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- ABBV's page on the SEC website